Empowered Patient Podcast

Dr. Steve Marcus, CEO of Cantex Pharmaceuticals,  emphasizes the importance of the RAGE receptor in diseases like cancer and inflammation.  Their lead compound, azeliragon, blocks the activation of the RAGE receptor and shows effectiveness in inhibiting cancer metastasis and enhancing the impact of radiation. Clinical trials are underway for breast cancer, pancreatic cancer, glioblastoma, and COVID-19. This approach addresses the cancer cells and the microenvironment in which they reside to reduce disease progression and alter the immune environment. Steve explains, "RAGE is a receptor on the surface of cells that sends signals to the cell that can either enhance or harm health. When over-activated, RAGE has been implicated in a wide range of inflammatory diseases and cancers. In cancer, in particular, over-activation of RAGE has been associated with both the invasiveness of cancer, with the progression of cancer, and with metastasis of cancer."   "Azeliragon blocks the binding of anything that can activate